ASTRAZENECA PLC ADR (NASDAQ: AZN)

ASTRAZENECA PLC ADR

NASDAQ: AZN (Astrazeneca PLC)

最近更新时间: 02 Jan, 7:54PM

91.57

-0.36 (-0.39%)

加入群组

前收盘价格	91.93
收盘价格	92.39
成交量	3,250,721
平均成交量 (3个月)	5,115,172
市值	283,918,925,824

市盈率 (P/E TTM)	30.63
预期市盈率 (P/E Forward)	18.32
价格/销量 (P/S)	5.07
股市价格/股市净资产 (P/B)	6.38

52周波幅	61.24 (-33%) — 94.02 (2%)
利润日期	10 Feb 2026
股息率 (DY TTM)	1.71%

市场趋势

		短期	中期
行业	Drug Manufacturers - General (US)	看涨	混合的
	Drug Manufacturers - General (全球的)	看涨	混合的
股票	Astrazeneca PLC	混合的	混合的

AIStockmoo 评分

1.1

分析师共识	2.0
内部交易活动	NA
价格波动	-0.5
技术平均移动指标	1.0
技术振荡指标	2.0
平均	1.13

相关股票

股票	市值	DY	P/E（TTM）	P/B
AZN	284 B	1.71%	30.63	6.38
SNY	117 B	4.57%	15.70	1.34
AMGN	173 B	2.97%	24.80	18.50
GILD	154 B	2.54%	19.26	7.19
BIIB	26 B	-	15.93	1.51
GRFS	8 B	1.88%	14.44	1.01

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
部门	Healthcare
行业	Drug Manufacturers - General
投资方式	Large Core
机构持股比例	17.13%

该时间范围内无数据。

日期	类型	细节
20 Jan 2026	CNBC	Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry
10 Jan 2026	CNBC	2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market
08 Jan 2026	公告	Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit
22 Dec 2025	公告	ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer
19 Dec 2025	CNBC	Nine of the largest pharma companies ink deals with Trump to lower drug prices
15 Dec 2025	公告	ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
04 Dec 2025	公告	Salesforce’s Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement
04 Dec 2025	公告	AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH
02 Dec 2025	公告	Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
26 Nov 2025	公告	IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers
21 Nov 2025	公告	AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth
09 Nov 2025	公告	Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial
07 Nov 2025	公告	Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease
06 Nov 2025	公告	AstraZeneca's 9M and Q3 2025 Financial Results
06 Nov 2025	公告	Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
06 Nov 2025	CNBC	Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
29 Oct 2025	CNBC	Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound
显示更多

股息率 (DY TTM)	1.71%
5年平均股息收益率	2.13%
股息支付比率	62.37%
预计下次股息支付	Mar 2026

除息日	公告日期	支付日期	详情
08 Aug 2025	29 Jul 2025	08 Sep 2025	0.515 现金
21 Feb 2025	06 Feb 2025	24 Mar 2025	1.05 现金
09 Aug 2024	25 Jul 2024	09 Sep 2024	0.5 现金
22 Feb 2024	08 Feb 2024	25 Mar 2024	0.985 现金
10 Aug 2023	28 Jul 2023	11 Sep 2023	0.465 现金
23 Feb 2023	09 Feb 2023	27 Mar 2023	0.985 现金
11 Aug 2022	29 Jul 2022	12 Sep 2022	0.465 现金
24 Feb 2022	10 Feb 2022	28 Mar 2022	0.985 现金
12 Aug 2021	29 Jul 2021	13 Sep 2021	0.45 现金
25 Feb 2021	11 Feb 2021	29 Mar 2021	0.95 现金
13 Aug 2020	30 Jul 2020	14 Sep 2020	0.45 现金
27 Feb 2020	14 Feb 2020	30 Mar 2020	0.95 现金
08 Aug 2019	29 Jul 2019	09 Sep 2019	0.45 现金
28 Feb 2019	14 Feb 2019	27 Mar 2019	0.95 现金
09 Aug 2018	26 Jul 2018	10 Sep 2018	0.45 现金
15 Feb 2018	02 Feb 2018	19 Mar 2018	0.95 现金
09 Aug 2017	28 Jul 2017	11 Sep 2017	0.45 现金
15 Feb 2017	02 Feb 2017	20 Mar 2017	0.95 现金
10 Aug 2016	28 Jul 2016	12 Sep 2016	0.45 现金
17 Feb 2016	05 Feb 2016	21 Mar 2016	0.95 现金
12 Aug 2015	30 Jul 2015	14 Sep 2015	0.45 现金
18 Feb 2015	09 Feb 2015	23 Mar 2015	1.9 现金
13 Aug 2014	31 Jul 2014	15 Sep 2014	0.9 现金
19 Feb 2014	07 Feb 2014	24 Mar 2014	1.9 现金
14 Aug 2013	01 Aug 2013	16 Sep 2013	0.9 现金
13 Feb 2013	31 Jan 2013	18 Mar 2013	1.9 现金
08 Aug 2012	26 Jul 2012	10 Sep 2012	0.9 现金
15 Feb 2012	02 Feb 2012	19 Mar 2012	1.95 现金
04 Aug 2011	28 Jul 2011	12 Sep 2011	0.85 现金
02 Feb 2011	27 Jan 2011	14 Mar 2011	1.85 现金
04 Aug 2010	29 Jul 2010	13 Sep 2010	0.7 现金
03 Feb 2010	28 Jan 2010	15 Mar 2010	1.71 现金
05 Aug 2009	30 Jul 2009	14 Sep 2009	0.59 现金
04 Feb 2009	29 Jan 2009	16 Mar 2009	1.5 现金
06 Aug 2008	31 Jul 2008	15 Sep 2008	0.55 现金
07 Feb 2008	04 Feb 2008	17 Mar 2008	1.35 现金
08 Aug 2007	27 Jul 2007	17 Sep 2007	0.52 现金
07 Feb 2007	01 Feb 2007	19 Mar 2007	1.23 现金
09 Aug 2006	27 Jul 2006	18 Sep 2006	0.49 现金
08 Feb 2006	02 Feb 2006	20 Mar 2006	0.92 现金
10 Aug 2005	29 Jul 2005	19 Sep 2005	0.38 现金
09 Feb 2005	27 Jan 2005	21 Mar 2005	0.645 现金
11 Aug 2004	22 Jul 2004	20 Sep 2004	0.295 现金
显示更多

每年股息收益率

年份	每年总股息 ($)	频率/年份	收益率 %
2025	1.57	2	1.70
2024	1.49	2	2.27
2023	1.45	2	2.15
2022	1.45	2	2.14
2021	1.40	2	2.40
2020	1.40	2	2.80
2019	1.40	2	2.81
2018	1.40	2	3.69
2017	1.40	2	4.04
2016	1.40	2	5.12
2015	2.35	2	6.92
2014	2.80	2	7.96
2013	2.80	2	9.43
2012	2.85	2	12.06
2011	2.70	2	11.67
2010	2.41	2	10.44
2009	2.09	2	8.91
2008	1.90	2	9.26
2007	1.75	2	8.17
2006	1.41	2	5.27
2005	1.03	2	4.22
2004	0.295	1	1.62
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

请登录以添加到您的群组

AI 建议策略模板

自定义的价格提醒

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

请登录以添加到您的群组

已实现利润	-
未实现利润	-
收到股息 2026	-
利润总额	-
平均回报	-
数量(购买)	-
平均价格(购买)	-
数量(卖出)	-
平均价格(卖出)	-

请登录以添加到您的群组

没有符合您标准的股票

营业毛利率	14.14%
营业利益率 (TTM)	27.94%
稀释每股收益 (EPS TTM)	2.48
季度收入增长率 (YOY)	7.20%
季度盈利增长率 (YOY)	33.80%

总债务/股东权益 (D/E MRQ)	77.11%
流动比率 (MRQ)	0.900
营业现金流 (OCF TTM)	13.09 B
杠杆自由现金流 (LFCF TTM)	9.35 B

资产报酬率 (ROA TTM)	8.16%
股东权益报酬率 (ROE TTM)	19.79%

安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)